MIRA INFORM REPORT

 

 

Report No. :

330052

Report Date :

15.07.2015

 

IDENTIFICATION DETAILS

 

Name :

FARMACEUTICA PARAGUAYA S.A.

 

 

Registered Office :

Avda. Aviadores del Chaco 2462 entre Santa Teresa y San Blas, Asuncion, Republic of Paraguay

 

 

Country :

Paraguay

 

 

Year of Establishment :

1975

 

 

Legal Form :

Public Limited Company

 

 

Line of Business :

Subject is engaged in processing and marketing of medical specialties

 

 

No. of Employee :

500

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No complaints

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Paraguay

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

PARAGUAY - ECONOMIC OVERVIEW

 

Landlocked Paraguay has a market economy distinguished by a large informal sector, featuring re-export of imported consumer goods to neighboring countries, as well as the activities of thousands of microenterprises and urban street vendors. A large percentage of the population, especially in rural areas, derives its living from agricultural activity, often on a subsistence basis. Because of the importance of the informal sector, accurate economic measures are difficult to obtain. On a per capita basis, real income has stagnated at 1980 levels. The economy grew rapidly between 2003 and 2008 as growing world demand for commodities combined with high prices and favorable weather to support Paraguay's commodity-based export expansion. Paraguay is the sixth largest soy producer in the world. Drought hit in 2008, reducing agricultural exports and slowing the economy even before the onset of the global recession. The economy fell 3.8% in 2009, as lower world demand and commodity prices caused exports to contract. The government reacted by introducing fiscal and monetary stimulus packages. Growth resumed at a 13% level in 2010, the highest in South America, but slowed in 2011-13 as the stimulus subsided and severe drought and outbreaks of foot-and-mouth disease led to a drop in beef and other agricultural exports. The economy took another leap in 2014, largely due to strong export growth. Political uncertainty, corruption, limited progress on structural reform, and deficient infrastructure are the main obstacles to long-term growth.

 

Source : CIA

 

 Company Name 

 

 

FARMACEUTICA PARAGUAYA S.A.

*FAPASA*

R.U.C. Nº 80006276-0

 

 

 Summary 

 

 

BEGINNER OF ACTIVITIES, INCORPORATED IN 1975. NO FINANCIAL DATA PROVIDED ONLY TO BANKS AND TAX COMPTROLLERS. APT FOR NEW CREDITS.
UNFORTUNATELY THIS COMPANY CONTINUES WITH HIS DECISION NOT TO GIVE DATAS, NO NEGATIVE REGISTERED.

 

 

 Operations 

 

 

PROCESSING AND MARKETING OF MEDICAL SPECIALTIES FOR HUMAN USE.

 

 

 Legal Structure 

 

 

LEGAL FORM:         PUBLIC LIMITED COMPANY
CREATED:            1975
REGISTERED RPC:     1975
DURATION:           UNLIMITED
END OF FISCAL YEAR: 31.12

 

 

 Contact 

 

 

Accountant: Liliana Garcete

Legal and administrative address:
Avda. Aviadores del Chaco 2462 entre Santa Teresa y San Blas, Asuncion, Republic of Paraguay.

Phone:  00595-21 614450/4
E.Mail: liliana.garcete@fapasa.com.py
Web:    www.fapasa.com.py

 

 

 Partners 

 

 

LEGAL REPRESENTATIVE:   OSVALDO FORMENTO

Using signature: It is in charge of before mentioned.

 

 

 History 

 

 

Reference activities were initiated directly by the company, which is engaged in the development, production and marketing of medicines for human use.

In 2004, health authorities in Argentina, Uruguay and Paraguay holder awarded to GMP compliance certification for the marketing of products in MERCOSUR. It exports to Brazil and has won approval from the health authorities of Pakistan, Colombia, Mexico, so the recertification cone with scope to Argentina and Paraguay, for 5 years.

The company has licenses for the following international laboratories:

CELGENE (EE.UU-SUIZA)
ALPHEX PHARMA (SUIZA)
TOLMAR (USA)
MEIJI SEIKA (JAPON)
DEBIOPHARM (SUIZA)
LABORATORIOS PHOENIX (ARGENTINA)

 

 

 Economic-Financial Position 

 

 

Continued with the policy of not provided financial information to third parties.

 

 

 Assets 

 

 

A society is given possession of the property in which it operates its head office and production plant, which by their characteristics have a significant value of realization.

It also has several vehicles of different models.

 

 

 Evolution and Results 

 

 

Is dedicated to the development of the abovementioned activities.

Imports from Brazil, Argentina, India, Switzerland and exports to Brazil, Argentina, Colombia, Mexico and Pakistan.

CELGENE (SWITZERLAND)
ALPEX PHARMA (SWITZERLAND)
DEBIOPHARM (SWITZERLAND)

licenses
----------

   Celgene (USA - Switzerland). REVLIMID for the product.
   ALPEX PHARMA (Switzerland). For the product APELSIN® VITAMIN C.
   TOLMAR (USA). Eligard® for 7.5 Product and 22,5mg.
   Meiji Seika CO. (Japan). For the Product SUPRAHYAL® 25mg inj.
   Debiopharm S.A. (Switzerland). 3.75 Product for Decapeptyl® and 11,25mg.
   PHOENIX SAICF LABORATORIES (Argentina). Product UROFLAX® for comp CR 10 mg controlled release.

* 500 EMPLOYEES

 

 

 Branches 

 

 

Plant of production:
--------------------
Waldino Ramon Lovera y del Carmen, Fernando de la Mora, Republic of Paraguay.

Branchs:
--------
Gral. Eugenio Garay nº 112 esq. Juan A. Roa, Cnel. Oviedo, Paraguay.

- Calle UV Monday, Ciudad del Este, Paraguay.

- Gral. Cabañas 235, Encarnacion, Paraguay.

 

 

 Payment Record and Credit Risk 

 

 

BANCO ATLAS
BANCO CONTINENTAL
BANCO REGIONAL

Centralhouse

INSURANCE:
----------
MAPFRE S.A.

 

 

 Concept 

 

 

It is commercially related to companies of this one and other places, good part of which offer its credit support without making until the moment objections on the modes of payment that it sustains.

* FULFILLMENT: NOT OBJECTED.

 

 

 Final Opinion 

 

 

The lack of negative antecedents makes anew viable the credit relation with the company, by current credits and additional guarantees.

* APT FOR NEW CREDITS.

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.63.50

UK Pound

1

Rs.98.20

Euro

1

Rs.69.73

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

ASH

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.